Skip to main content
Premium Trial:

Request an Annual Quote

With 2.5M Euros in Funding, EU Consortium Sets Eyes on Finding Genomic Cure for Liver Cancer

NEW YORK, Feb. 23 (GenomeWeb News) - PONT (Parallel Optimization of New Technologies for Post-Genomics Drug Discovery), a research project piloted by British, Austrian, and German biotech companies and academic researchers, will be using 2.5 million in European Union grant money to find genome targets in liver cancer, project leaders said yesterday.

PONT representatives said they will rely on a strategy of parallel pre-clinical drug development, rather than sequential, to lessen the time it takes to bring a drug to trial. Other areas they are concentrating on are human tissue resources, RNA technology, and structural proteomics.

PONT received the funding in May 2004 from the EU's 6th Framework Program. The consortium is led by Graz, Austria-based Oridis Biomed; the Medical University of Graz' Institute of Pathology;  Berlin-based PSF Biotech; the Free University of Berlin's Institute of Crystallography; Munich, Germany-based Nascacell IP; and the Bude, UK-based Tripos Receptor Research.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.